Overall success of cannulation · people with biliary cannulation for the prevention of post‐ERCP pancreatitis
Pancreatic duct guidewire (PGW) or double guidewire technique (DGT) showed no clear difference in overall cannulation success compared with other endoscopic techniques (low certainty).
1 finding from 1 review
Post‐ERCP bleeding · people with biliary cannulation for the prevention of post‐ERCP pancreatitis
Pancreatic duct guidewire (PGW) or double guidewire technique (DGT) showed no clear difference in post‐ERCP bleeding compared with other endoscopic techniques (low certainty).
1 finding from 1 review
Post‐ERCP perforation · people with biliary cannulation for the prevention of post‐ERCP pancreatitis
Pancreatic duct guidewire (PGW) or double guidewire technique (DGT) showed no clear difference in post‐ERCP perforation compared with other endoscopic techniques (low certainty).
1 finding from 1 review
Post‐ERCP cholangitis · people with biliary cannulation for the prevention of post‐ERCP pancreatitis
Pancreatic duct guidewire (PGW) or double guidewire technique (DGT) showed no clear difference in post‐ERCP cholangitis compared with other endoscopic techniques (low certainty).
1 finding from 1 review
All‐cause mortality · people with biliary cannulation for the prevention of post‐ERCP pancreatitis
Pancreatic duct guidewire (PGW) or double guidewire technique (DGT) showed no clear difference in mortality compared with other endoscopic techniques (low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants experiencing an adverse event of permanent diplopia (double vision) Reports of diplopia across all measured time points · 5‐ to 8‐year‐old children with amblyopia
1 finding from 1 review
Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in progression‐free survival (taxane‐containing doublet therapy vs… compared with chemotherapy (low certainty).
1 finding from 1 review
Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
Sleep onset latency Participant reports. Scale from 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Intervention not reported
Wake time after sleep onset Participant reports. Scale from: 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Intervention not reported
Total sleep time Participant reports. Scale from: 300 to 840; more minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Intervention not reported
Next‐day alertness Participant reports. Scale from: 0 to 10 points; higher scores equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Intervention not reported
Serious adverse events (as defined in the primary study) Participant reports. Serious adverse events observed during double‐blind treatment period · Patients with insomnia
1 finding from 1 review
Lack of efficacy withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain
1 finding from 1 review